trial

Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia

NCTId NCT01213524
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 75 (actual)
Sponsored by Brown University
Primary completion 2011-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
75 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2005-09
Primary completion
2011-03
Eligibility
ALL · 18 Years · 99 Years

Interventions & indications

Drugs
42 mg transdermal nicotine replacementsensorimotor replacementusual brand smoking

Sponsors

Brown UniversityLead Sponsor
National Institute on Drug Abuse (NIDA)Collaborator

Investigators

1
Jennifer Tidey, Ph.D.Principal Investigator

Sites

1 total
Providence, United States

Linked catalysts

1
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia — primary completion2011-03

Facts & assertions

4 sourced
Enrollment
75
Phase
PHASE2
Primary Completion Date
2011-03
Status
COMPLETED
relationships
The graph out of here
drug
42 mg transdermal nicotine replacement
drug
sensorimotor replacement
drug
usual brand smoking
drug
lead_sponsor
Brown University
company
collaborator
National Institute on Drug Abuse (NIDA)
company
indication
Tobacco Use Disorder
indication
Schizophrenia
indication
Tobacco Use Disorder
indication
investigator
Jennifer Tidey, Ph.D.
person